



CBD and THC analysis in GMP regime

The interest on medical use of cannabis and cannabinoids is increasing and this type of studies are extremely dynamic. Nowadays there are two types of cannabis products: medicinal products with marketing authorization and cannabis (magistral) preparations.

The regulation of cannabis and cannabinoids for medical purposes around the world presents a complex system of approaches. To date there is no harmonized EU standard or pharmacopoeia monograph for medical cannabis and extracts. The cannabis products should be followed the national legislations and local guidelines. Furthermore, several European countries have published specific pharmacopoeia monographs for cannabis flowers (e.g., the German DAB Monograph, the Draft DK Monograph) and extracts (German draft monograph).

The use and acceptance of medicinal cannabis continues to evolve, in fact several countries, as Israel, Canada, Germany, and the Netherlands, have changed their regulations to allow patient access to medical Cannabis and related products.

Legislation governing use of medicinal cannabis continues to evolve rapidly and for this reason is important the presence of a specific quality standard for this kind of products.

The quality standard should include a control to any contamination or adulteration as derived from the use of pesticides, assay limits for active ingredients, microbiological contamination, heavy metals, absence of aflatoxins, ochratoxin A, foreign matter, residual solvents, and other specific tests based on the risk analysis of the products.

Neutron proposal

To date Neutron pharma department is active on analysis of THC $\Delta 8 / \Delta 9$ and CBD on finished pharmaceutical grade products, botanical extracts, CBD oil.

Among the activities offered we find:

- **DAC monography for Cannabidiol**
- **Method validation for Assay (CBD) and THC Impurities on FP**

The laboratory can support the customer from an analytical point of view, requesting the appropriate ministerial authorizations for the handling of substances, throughout the supply chain from the raw material to the finished product.

Starting/Raw material



Finished Product

(E.g., Hemp) Neutron proposal: Contaminants

(E.g., CBD Oil) Neutron proposal: CBD, THC $\Delta 8 / \Delta 9$

To request an analysis, or to learn more about this specific topic, please do not hesitate to contact the Neutron team <https://www.neutron.it/en/contacts>.